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only the first episode of liver abscess during the study period was analysed. Four patients could not be stabilised with intravenous antibiotic treatment and finally succumbed. One patient was successfully treated with oral antibiotic alone and was excluded from the analysis. In total, 112 patients were analysed. Continuous intravenous antibiotic therapy was administered to 55 patients (group I) and sequential intravenous-oral antibiotic therapy to 57 patients (group II). No power calculations were performed. There was no evidence that the initial study sample was appropriate for the clinical study question.
Study design
The basis of the analysis was a retrospective cohort study. All the patients were followed-up at the outpatient clinic of the same institution after discharge. The median period of follow-up was 27.5 months for group I (continuous therapy) and 21.0 months for group II (sequential therapy).
Analysis of effectiveness
All the patients included in the study were accounted for in the analysis. The health outcomes examined were inhospital mortality, length of hospital stay and relapse rates. The two groups were comparable in terms of baseline characteristics (age, gender, race), incidence of non-malignant co-morbidities, clinical presentations, microbiological and imaging findings, time to stabilisation after hospital admission, and frequency of the drainage procedures. All patients received intravenous broad-spectrum antibiotics initially. Potential confounding factors were adjusted for using logistic regression analysis.
Effectiveness results
There were 3 in-hospital deaths in group I (continuous therapy) and none in group II (sequential therapy), (p=0.11).
The median length of hospital stay was 42 days (interquartile range, IQR=5.0) in group I and 28 days (IQR=12.0) in group II, (p<0.01).
During follow-up there was no recurrence of liver abscess within 6 weeks after the cessation of antibiotic treatment.
On longer follow-up, one patient in group I with cryptogenic liver abscess had a liver abscess recur in a different lobe 16 months after the initial presentation.
In group II, two patients had a recurrence in the 5th and 33rd months.
Clinical conclusions
A sequential intravenous-oral antibiotic regime was a safe and effective treatment for pyogenic liver abscess.
Measure of benefits used in the economic analysis
No summary measure of health benefit was used in the economic analysis and the clinical outcomes were left disaggregated. The economic analysis was, in effect, a cost-consequences analysis.
Direct costs
The perspective of the study was not stated, but it seems to have been that of a third-party payer. The costs were for medication and a hospital bed. It was not reported whether these cost elements included costs arising from treating potential adverse events, or additional tests and practices potentially needed in relation to the strategies under evaluation. The costs and the quantities were not analysed separately. The costs were estimated using actual data derived from patient records. The quantity of the resources used referred to the period from 1 January 1991 to 31 May 2000. The costs were calculated according to the charges for the year 2000 in Hong Kong. Discounting was, appropriately, not carried out since the costs were incurred during less than one year.
